FDA Refines Guidance On Immunogenicity Testing
Executive SummaryFDA’s final guidance on the development of assays used in clinical trials to evaluate the immunogenicity of therapeutic proteins provides more detail on where immunogenicity information is to be placed in BLAs, and adds appendix on a multi-tiered approach to anti-drug antibody testing.
You may also be interested in...
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
A plan to develop a “best practices” guide on validating rapid analytical methods for biopharmaceuticals is in the works.
The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.